| Document |
Document Title |
|
WO/2019/078452A1 |
The present invention relates to: a 4-benzopyranone derivative and a pharmaceutically acceptable salt, solvate, racemate or stereoisomer thereof; a composition for preventing, alleviating or treating TNF-related diseases, containing the ...
|
|
WO/2019/073064A1 |
The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 23 or higher and 83 or lower (in particular Ag1+, Ba2+,Pb2 +, Gd3+ and Bi3+) and one or more hematein ligand(s). In particular, th...
|
|
WO/2019/071353A1 |
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...
|
|
WO/2019/073065A1 |
The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 29 or higher and 83 or lower (preferably 29 or higher and 81 or lower) and one or more ligand(s) selected from the group consistin...
|
|
WO/2019/070807A1 |
Methods of treating a viral infection in a subject are provided. The methods include administering a therapeutically effective amount of a pharmaceutical composition comprising ginkgolic acid (GA) to the subject in need thereof, where th...
|
|
WO/2019/069297A2 |
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...
|
|
WO/2019/065532A1 |
Developed is a novel analgesic, the therapeutic targets of which are T-type calcium channels. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable...
|
|
WO/2019/063955A1 |
The present invention concerns the compounds of the following formula (I): (I) in which: - X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, - The X--Y bond and Y are absent if X represents an oxygen or sulfur ...
|
|
WO/2019/060986A1 |
Raw cannabis plant material is mixed with ethanol and spun-dry to extract cannabinoids. The ethanol may be chilled before adding it to the raw cannabis plant material, and a non-polar solvent stage may be used to increase the yield of th...
|
|
WO/2019/062876A1 |
Provided are a fluorescent probe, a preparation method therefor and a use thereof. The fluorescent probe responds to viscosity sensitively and specifically, can be used for the specific fluorescence label of proteins, and can also be use...
|
|
WO/2019/063848A1 |
The present invention relates to a method for producing, obtaining and enriching dronabinol (Δ9-THC) as well as natural substances from plant extracts.
|
|
WO/2019/062804A1 |
The present invention relates to a method for preparing an oxaspirocycle derivative, and an intermediate thereof. The method reduces reaction steps, improves reaction yield, is simple and easy to operate, and is favorable for industrial ...
|
|
WO/2019/067636A1 |
Methods are provided for identifying whether a cancer patient, and especially a breast cancer patient, will be responsive to treatment. Specified TOPO2A, IDO1 and/or p16 fragment peptides are precisely detected and quantitated by SRM-mas...
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said com...
|
|
WO/2019/059344A1 |
The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the for...
|
|
WO/2019/057821A1 |
The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
|
|
WO/2019/056123A1 |
Pharmaceutical compositions comprising one or more cannabinoids and a pharmaceutically acceptable carrier are disclosed. The compositions are in a form suitable for topical administration, and are useful in the treatment of pain. The can...
|
|
WO/2019/056128A1 |
Compositions comprising two or more cannabinoids, a terpene, and a flavonoid suitable for use in treating insomnia are disclosed. In preferred embodiments, the cannabinoids are cannabidiol and tetrahydrocannabinol, while the terpenes and...
|
|
WO/2019/056129A2 |
|
|
WO/2019/054386A1 |
Provided is a heterocyclic compound represented by general formula (I), or a pharmacologically acceptable salt of the heterocyclic compound. In general formula (I): X represents O or NH; R1 represents a substituted or unsubstituted aryl ...
|
|
WO/2019/054633A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/053605A1 |
The present invention provides an environmentally benign, facile process for preparation of Tocotrienols from commercially available derivatives of o-Cresol.
|
|
WO/2019/044672A1 |
[PROBLEM] To provide a novel method for synthesising a polyphenol. [SOLUTION] A polyphenol production method including the reaction of catechin in the presence of a catalyst and an oxidising agent, said catalyst comprising a metal oxide ...
|
|
WO/2019/043259A1 |
The invention relates to cannabinoids and their isolation and purification and to obtaining them by means of centrifugal partition chromatography and pH-zone refining.
|
|
WO/2019/043251A1 |
The present invention relates to novel compounds which are particularly useful for the synthesis of novel chromanol derivatives. These compounds have interesting properties. Particularly, the novel chromanol derivatives have interesting ...
|
|
WO/2019/044872A1 |
The present invention addresses the problem of providing a rhodamine-based dye which is capable of suppressing fluorescent yield and forming an aggregate even under low concentration conditions. The present invention pertains to a compou...
|
|
WO/2019/044736A1 |
The present invention provides a detection method and detection probe for colibactin and colibactin-producing bacteria. The present invention provides, for example, the detection of myristoyl-asparagine using a tissue sample or stool sam...
|
|
WO/2019/038361A1 |
The present invention relates to medicaments for use in the prophylaxis or treatment of vasoconstriction related disorders or conditions. Specifically, the present invention relates to (2R) enantiomeric form of a 6-chromanol derivative f...
|
|
WO/2019/038360A1 |
The present invention relates to the (S) enantiomeric form of certain 6-chromanol derivatives for use as a medicament. Especially, the present invention relates to the (S) enantiomeric form of a 6-chromanol derivative for use as a medica...
|
|
WO/2019/038739A1 |
Pharmaceutical and nutraceutical compositions suitable for transdermal administration of plant-derived medicinal compounds are disclosed. The compositions comprise ground plant material (plant flour) and a dermally acceptable adhesive. I...
|
|
WO/2019/033164A1 |
A method for demethylating a methylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C1-...
|
|
WO/2019/033168A1 |
method for decarboxylating a carboxylated phytocannabinoid compound of Formula I to form a phytocannabinoid compound of Formula II: Formula I Formula II wherein: R1 is selected from the group consisting of: substituted or unsubstituted C...
|
|
WO/2019/030631A1 |
The present invention relates to novel compounds based on 3- ketocoumarins, which are useful as photoinitiators and sensitizer and to compositions thereof. More particularly, the novel compounds comprise a polyhydroxy polymeric core, whi...
|
|
WO/2019/032609A1 |
Chromatography systems and methods for using carbon dioxide to separate one or more cannabis-derived compounds from other components of a mixture are generally described. Some of the methods described herein comprise transporting a mixtu...
|
|
WO/2019/027040A1 |
A compound represented by formula (1) (in the formula, R1-R8, R11-R18, R21-R28, R31-R38, X, Y, L1, L2, L3, and Ar are as defined in the specification) provides an organic electroluminescent element having a low drive voltage and exceptio...
|
|
WO/2019/027263A1 |
The present application provides a heterocyclic compound represented by Chemical Formula 1, and an organic light-emitting element including same.
|
|
WO/2019/023803A1 |
Powdered cannabis extracts and methods for obtaining powdered cannabis extracts are described. In an aspect, the present application describes a method of preparing a single-serve container which may be configured for receipt in a single...
|
|
WO/2019/022002A1 |
A compound represented by formula (I) or a salt thereof. (In formula (I), Q1 represents an (un)substituted C6-10 aryl group; Q2 represents an (un)substituted C1-6 alkyl group, an (un)substituted C6-10 aryl group, or a five- to ten-member...
|
|
WO/2019/019792A1 |
The present invention relates to a coumarin (ketone) oxime ester compound of formula (I), wherein the n and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compound has a very strong ultraviolet absorption in a range...
|
|
WO/2019/020738A1 |
The present invention describes a process for the production of (-)-cannabidiol (CBD) from industrial hemp by means of an extraction followed by two alternative working processes: a process A which provides extraction with solvents first...
|
|
WO/2019/018455A1 |
Methods of treating autoimmune microvascular conditions using diosmin or diosmetin are described, particularly the treatment of digital ulcers in systemic sclerosis.
|
|
WO/2019/013542A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.
|
|
WO/2019/012166A1 |
Compounds with a drimenyloxyarene structure and derivatives, and the use thereof to treat infections caused by phytopathogenic fungi, as fungistatic agents with a low ecological impact. The present invention comprises compounds with the ...
|
|
WO/2019/013249A1 |
A chromene compound showing a reduced matrix dependency and having at least one indenonaphthopyran structure which carries a group forming a spiro ring together with the carbon atom at the 13-position, wherein the indenonaphthopyran stru...
|
|
WO/2019/013526A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light emitting device comprising the same.
|
|
WO/2019/012000A1 |
The present invention relates to a novel synthetic pathway for alpha- tocopherol. The invention discloses different reactions yielding some new intermediates in a very high yield and stereoselectivity.
|
|
WO/2019/009257A1 |
The problem to be solved by the present invention is to provide a method for producing a flavone having a malonyl group added to glucose located at position-7 therein using a polynucleotide encoding a protein having an activity to transf...
|
|
WO/2019/007447A1 |
The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumours in the bone and surrounding tissue...
|
|
WO/2019/010419A1 |
A method for purification and separation of cannabinoids, such as cannabidiol and tetrahydrocannabinol, e.g., from the dried hemp and cannabis leaves can use a continuous simulated moving bed process and a combination of one or more of a...
|
|
WO/2019/004790A1 |
The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting element including same.
|
